

# Eugene K Cha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6610050/publications.pdf>

Version: 2024-02-01

88  
papers

5,528  
citations

71061

41  
h-index

79644

73  
g-index

93  
all docs

93  
docs citations

93  
times ranked

5744  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. <i>Nature Immunology</i> , 2003, 4, 1102-1110.	7.0	564
2	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	0.9	263
3	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	3.2	225
4	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	0.9	202
5	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	0.9	201
6	Impact of gender on bladder cancer incidence, staging, and prognosis. <i>World Journal of Urology</i> , 2011, 29, 457-463.	1.2	194
7	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	0.9	190
8	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 818-825.	0.9	188
9	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. <i>European Urology</i> , 2012, 61, 245-253.	0.9	168
10	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	3.2	164
11	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 854-855.	0.9	152
12	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	9.4	143
13	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	0.9	122
14	Tim-2 regulates T helper type 2 responses and autoimmunity. <i>Journal of Experimental Medicine</i> , 2005, 202, 437-444.	4.2	119
15	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 188, 398-404.	0.2	114
16	The impact of retransurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. <i>BJU International</i> , 2016, 118, 44-52.	1.3	110
17	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	0.9	98
18	Prognostic factors for upper urinary tract urothelial carcinoma. <i>Nature Reviews Urology</i> , 2011, 8, 440-447.	1.9	94

#	ARTICLE	IF	CITATIONS
19	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	0.9	93
20	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	3.2	85
21	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	1.3	77
22	Risk Factors for the Development of Parastomal Hernia after Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 1708-1713.	0.2	76
23	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	0.9	69
24	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , 2013, 111, 249-255.	1.3	67
25	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. <i>World Journal of Urology</i> , 2011, 29, 473-480.	1.2	62
26	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	0.9	61
27	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. <i>European Urology Focus</i> , 2019, 5, 104-108.	1.6	58
28	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 187, 845-851.	0.2	57
29	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e9-47.e14.	0.8	55
30	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	0.7	53
31	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	0.8	53
32	Nonneoplastic Renal Cortical Scarring at Tumor Nephrectomy Predicts Decline in Kidney Function. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 531-540.	1.2	52
33	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , 2011, 18, 616-629.	0.5	51
34	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	1.0	51
35	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723.	2.0	50
36	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. <i>BJU International</i> , 2013, 111, 404-411.	1.3	48

#	ARTICLE	IF	CITATIONS
37	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	0.9	47
38	Current status of robotic partial nephrectomy (RPN). <i>BJU International</i> , 2011, 108, 935-941.	1.3	46
39	Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. <i>BJU International</i> , 2012, 110, 1463-1470.	1.3	45
40	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. <i>Journal of Urology</i> , 2012, 187, 457-462.	0.2	43
41	Immunocytology Is a Strong Predictor of Bladder Cancer Presence in Patients With Painless Hematuria: A Multicentre Study. <i>European Urology</i> , 2012, 61, 185-192.	0.9	42
42	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
43	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 5-11.	1.2	39
44	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019, 248, 260-265.	2.1	37
45	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.2	36
46	Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. <i>British Journal of Cancer</i> , 2012, 107, 1826-1832.	2.9	34
47	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2012, 30, 753-759.	1.2	33
48	Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. <i>Urology</i> , 2016, 94, 148-153.	0.5	33
49	Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. <i>World Journal of Urology</i> , 2013, 31, 817-822.	1.2	31
50	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , 2012, 109, 685-690.	1.3	30
51	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.2	30
52	Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. <i>Current Urology Reports</i> , 2016, 17, 12.	1.0	30
53	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 201-204.	1.6	30
54	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	29

#	ARTICLE	IF	CITATIONS
55	Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). <i>BJU International</i> , 2012, 109, 968-985.	1.3	28
56	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , 2016, 17, 9.	1.0	28
57	Cost-effective treatment of low-risk carcinoma not invading bladder muscle. <i>BJU International</i> , 2013, 111, E78-84.	1.3	27
58	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	1.3	26
59	Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 217-225.	0.8	26
60	International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. <i>BJU International</i> , 2012, 110, 674-681.	1.3	24
61	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. <i>BJU International</i> , 2018, 122, 627-632.	1.3	24
62	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <i>World Journal of Urology</i> , 2012, 30, 847-852.	1.2	23
63	Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. <i>BJU International</i> , 2012, 110, 63-68.	1.3	20
64	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019, 5, 365-368.	1.6	20
65	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
66	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e23-e27.	0.9	19
67	Recent advances in robot-assisted radical cystectomy. <i>Current Opinion in Urology</i> , 2011, 21, 65-70.	0.9	16
68	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1716-1724.	0.8	15
69	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	2.9	14
70	Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 151.e9-151.e15.	0.8	13
71	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. <i>Journal of Urology</i> , 2020, 204, 677-684.	0.2	13
72	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9

#	ARTICLE	IF	CITATIONS
73	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. <i>BJU International</i> , 2022, 129, 463-469.	1.3	9
74	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. <i>Journal of Urology</i> , 2017, 198, 546-551.	0.2	8
75	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1427-1432.	0.5	8
76	Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy. <i>Urologic Clinics of North America</i> , 2015, 42, 189-199.	0.8	7
77	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	0.9	7
78	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
79	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , 2018, 122, 121-126.	0.5	5
80	Stage pT0 after Radical Cystectomy: Are All Patients Equal?. <i>European Urology</i> , 2011, 60, 603-604.	0.9	4
81	Low yield of surveillance imaging after surgery for T1 kidney cancer. <i>World Journal of Urology</i> , 2016, 34, 949-953.	1.2	4
82	Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 T 197-200.	0.5	4
83	Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation. <i>European Urology</i> , 2015, 67, 350-351.	0.9	3
84	Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. <i>BJU International</i> , 2012, 109, 613-614.	1.3	2
85	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 645-653.	1.2	2
86	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. <i>Journal of Urology</i> , 2020, 204, 460-465.	0.2	2
87	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 281-281.	0.8	0
88	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 684-684.	0.2	0